Heregulin-induced VEGF expression via the ErbB3 signaling pathway in colon cancer

Digestion

Volumn 80, Issue 4, 2009, Pages 215-225

  Yonezawa, Masaoki ^a   Wada, Ken ^a   Tatsuguchi, Atsushi ^a   Akamatsu, Tomonori ^a   Gudis, Katya ^a   Seo, Tsuguhiko ^a   Mitsui, Keigo ^a   Nagata, Kazuhiro ^a   Tanaka, Shu ^a   Fujimori, Shunji ^a   Sakamoto, Choitsu ^a  

^a NIPPON MEDICAL SCHOOL   (Japan)

Author keywords

Colorectal carcinoma; ErbB3; Heregulin; Signal transduction; Vascular endothelial growth factor

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 3; MITOGEN ACTIVATED PROTEIN KINASE P38; NEU DIFFERENTIATION FACTOR; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN P85; VASCULOTROPIN;

ARTICLE; AUTOCRINE EFFECT; CANCER CELL CULTURE; CELL STRAIN CACO 2; COLON CANCER; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PARACRINE SIGNALING; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN SECRETION; PROTEIN TARGETING; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TUMOR BIOPSY; WESTERN BLOTTING;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ADENOCARCINOMA; CACO-2 CELLS; COLONIC NEOPLASMS; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HT29 CELLS; HUMANS; IMMUNOHISTOCHEMISTRY; INTESTINAL MUCOSA; MAP KINASE SIGNALING SYSTEM; NEUREGULIN-1; PHOSPHORYLATION; POLYMERASE CHAIN REACTION; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR, ERBB-3; RNA, MESSENGER; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 70349594194     PISSN: 00122823     EISSN: None     Source Type: Journal    
DOI: 10.1159/000229775     Document Type: Article

References (42)

1. Downward J, Yarden Y, Mayes E, Scrace G, Totty N, Stockwell P, Ullrich A, Schlessinger J, Waterfield MD: Close similarity of epidermal growth factor receptor and v-erb-B oncogene protein sequences. Nature 1984; 307: 521-527.
2. Bargmann CI, Hung MC, Weinberg RA: The neu oncogene encodes an epidermal growth factor receptor-related protein. Nature 1986; 319: 226-230.
3. Kraus MH, Issing W, Miki T, Popescu NC, Aaronson SA: Isolation and characterization of ERBB3, a third member of the ERBB/epidermal growth factor receptor family: evidence for overexpression in a subset of human mammary tumors. Proc Natl Acad Sci USA 1989; 86: 9193-9197.
4. Plowman GD, Culouscou JM, Whitney GS, Green JM, Carlton GW, Foy L, Neubauer MG, Shoyab M: Ligand-specific activation of HER4/p180 erbB4 , a fourth member of the epidermal growth factor receptor family. Proc Natl Acad Sci USA 1993; 90: 1746-1750.
5. Modjtahedi H, Affleck K, Stubberfield C, Dean C: EGFR blockade by tyrosine kinase inhibitor or monoclonal antibody inhibits growth, directs terminal differentiation and induces apoptosis in the human squamous cell carcinoma HN5. Int J Oncol 1998; 13: 335-342.
6. Nagy P, Arndt-Jovin DJ, Jovin TM: Small interfering RNAs suppress the expression of endogenous and GFP-fused epidermal growth factor receptor (erbB1) and induce apoptosis in erbB1-overexpressing cells. Exp Cell Res 2003; 285: 39-49.
7. Zhang M, Zhang X, Bai CX, Chen J, Wei MQ: Inhibition of epidermal growth factor receptor expression by RNA interference in A549 cells. Acta Pharmacol Sin 2004; 25: 61-67.
8. Evangelopoulos ME, Weis J, Kruttgen A: Signalling pathways leading to neuroblastoma differentiation after serum withdrawal: HDL blocks neuroblastoma differentiation by inhibition of EGFR. Oncogene 2005; 24: 3309-3318.
9. Choudhury A, Charo J, Parapuram SK, Hunt RC, Hunt DM, Seliger B, Kiessling R: Small interfering RNA (siRNA) inhibits the expression of the Her2/neu gene, upregulates HLA class I and induces apoptosis of Her2/ neu positive tumor cell lines. Int J Cancer 2004; 108: 71-77.
10. Hu YP, Venkateswarlu S, Sergina N, Howell G, St Clair P, Humphrey LE, Li W, Hauser J, Zborowska E, Willson JK, Brattain MG: Reorganization of ErbB family and cell survival signaling after knock-down of ErbB2 in colon cancer cells. J Biol Chem 2005; 280: 27383-27392.
11. Sithanandam G, Fornwald LW, Fields J, Anderson LM: Inactivation of ErbB3 by siRNA promotes apoptosis and attenuates growth and invasiveness of human lung adenocarcinoma cell line A549. Oncogene 2005; 24: 1847-1859.
12. Long W, Wagner KU, Lloyd KC, Binart N, Shillingford JM, Hennighausen L, Jones FE: Impaired differentiation and lactational failure of Erbb4-deficient mammary glands identify ERBB4 as an obligate mediator of STAT5. Development 2003; 130: 5257-5268.
13. Oliveira MJ, Lauwaet T, De Bruyne G, Mareel M, Leroy A: Listeria monocytogenes produces a pro-invasive factor that signals via ErbB2/ErbB3 heterodimers. J Cancer Res Clin Oncol 2005; 131: 49-59.
14. Plowman GD, Green JM, Culouscou JM, Carlton GW, Rothwell VM, Buckley S: Heregulin induces tyrosine phosphorylation of HER4/p180erbB4. Nature 1993; 366: 473-475.
15. Carraway KL 3rd, Sliwkowski MX, Akita R, Platko JV, Guy PM, Nuijens A, Diamonti AJ, Vandlen RL, Cantley LC, Cerione RA: The erbB3 gene product is a receptor for heregulin. J Biol Chem 1994; 269: 14303-14306.
16. Noguchi H, Sakamoto C, Wada K, Akamatsu T, Uchida T, Tatsuguchi A, Matsui H, Fukui H, Fujimori T, Kasuga M: Expression of heregulin alpha, erbB2, and erbB3 and their influences on proliferation of gastric epithelial cells. Gastroenterology 1999; 117: 1119-1127.
17. Jackson JG, St Clair P, Sliwkowski MX, Brattain MG: Blockade of epidermal growth factor- or heregulin-dependent ErbB2 activation with the anti-ErbB2 monoclonal antibody 2C4 has divergent downstream signaling and growth effects. Cancer Res 2004; 64: 2601-2609.
18. Vadlamudi R, Mandal M, Adam L, Steinbach G, Mendelsohn J, Kumar R: Regulation of cyclooxygenase-2 pathway by HER2 receptor. Oncogene 1999; 18: 305-314.
19. Venkateswarlu S, Dawson DM, St Clair P, Gupta A, Willson JK, Brattain MG: Autocrine heregulin generates growth factor independence and blocks apoptosis in colon cancer cells. Oncogene 2002; 21: 78-86.
20. Kapitanovic S, Radosevic S, Kapitanovic M, Andelinovic S, Ferencic Z, Tavassoli M, Primorac D, Sonicki Z, Spaventi S, Pavelic K, Spaventi R: The expression of p185(HER-2/ neu) correlates with the stage of disease and survival in colorectal cancer. Gastroenterology 1997; 112: 1103-1113.
21. Kapitanovic S, Radosevic S, Slade N, Kapitanovic M, Andelinovic S, Ferencic Z, Tavassoli M, Spaventi S, Pavelic K, Spaventi R: Expression of erbB-3 protein in colorectal adenocarcinoma: correlation with poor survival. J Cancer Res Clin Oncol 2000; 126: 205-211.
22. Yang W, Klos K, Yang Y, Smith TL, Shi D, Yu D: ErbB2 overexpression correlates with increased expression of vascular endothelial growth factors A, C, and D in human breast carcinoma. Cancer 2002; 94: 2855-2861.
23. Linderholm B, Andersson J, Lindh B, Beckman L, Erlanson M, Edin K, Tavelin B, Grankvist K, Henriksson R: Overexpression of c-erbB-2 is related to a higher expression of vascular endothelial growth factor (VEGF) and constitutes an independent prognostic factor in primary node-positive breast cancer after adjuvant systemic treatment. Eur J Cancer 2004; 40: 33-42.
24. Landriscina M, Cassano A, Ratto C, Longo R, Ippoliti M, Palazzotti B, Crucitti F, Barone C: Quantitative analysis of basic fibroblast growth factor and vascular endothelial growth factor in human colorectal cancer. Br J Cancer 1998; 78: 765-770.
25. Werther K, Christensen IJ, Nielsen HJ: Prognostic impact of matched preoperative plasma and serum VEGF in patients with primary colorectal carcinoma. Br J Cancer 2002; 86: 417-423.
26. De Vita F, Orditura M, Lieto E, Infusino S, Morgillo F, Martinelli E, Castellano P, Romano C, Ciardiello F, Catalano G, Pignatelli C, Galizia G: Elevated perioperative serum vascular endothelial growth factor levels in patients with colon carcinoma. Cancer 2004; 100: 270-278. (Pubitemid 38063634)
27. Hellyer NJ, Cheng K, Koland JG: ErbB3 (HER3) interaction with the p85 regulatory subunit of phosphoinositide 3-kinase. Biochem J 1998; 333: 757-763.
28. Yen L, You XL, Al Moustafa AE, Batist G, Hynes NE, Mader S, Meloche S, Alaoui-Jamali MA: Heregulin selectively upregulates vascular endothelial growth factor secretion in cancer cells and stimulates angiogenesis. Oncogene 2000; 19: 3460-3469.
29. Shibata A, Nagaya T, Imai T, Funahashi H, Nakao A, Seo H: Inhibition of NF-kappaB activity decreases the VEGF mRNA expression in MDA-MB-231 breast cancer cells. Breast Cancer Res Treat 2002; 73: 237-243.
30. Xiong S, Grijalva R, Zhang L, Nguyen NT, Pisters PW, Pollock RE, Yu D: Up-regulation of vascular endothelial growth factor in breast cancer cells by the heregulin-beta1- activated p38 signaling pathway enhances endothelial cell migration. Cancer Res 2001; 61: 1727-1732.
31. Scheidereit C: Signal transduction: docking IkappaB kinases. Nature 1998; 395: 225-226.
32. De Alvaro C, Teruel T, Hernandez R, Lorenzo M: Tumor necrosis factor alpha produces insulin resistance in skeletal muscle by activation of inhibitor kappaB kinase in a p38 MAPK-dependent manner. J Biol Chem 2004; 279: 17070-17078.
33. Je JH, Lee JY, Jung KJ, Sung B, Go EK, Yu BP, Chung HY: NF-kappaB activation mechanism of 4-hydroxyhexenal via NIK/IKK and p38 MAPK pathway. FEBS Lett 2004; 566: 183-189.
34. Chen D, Xu LG, Chen L, Li L, Zhai Z, Shu HB: NIK is a component of the EGF/heregulin receptor signaling complexes. Oncogene 2003; 22: 4348-4355.
35. Maurer CA, Friess H, Kretschmann B, Zimmermann A, Stauffer A, Baer HU, Korc M, Buchler MW: Increased expression of erbB3 in colorectal cancer is associated with concomitant increase in the level of erbB2. Hum Pathol 1998; 29: 771-777.
36. Sano H, Kawahito Y, Wilder RL, Hashiramoto A, Mukai S, Asai K, Kimura S, Kato H, Kondo M, Hla T: Expression of cyclooxygenase- 1 and -2 in human colorectal cancer. Cancer Res 1995; 55: 3785-3789.
37. Tsujii M, Kawano S, Tsuji S, Sawaoka H, Hori M, DuBois RN: Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 1998; 93: 705-716.
38. Sinicrope FA, Gill S: Role of cyclooxygenase- in colorectal cancer. Cancer Metastasis Rev 2004; 23: 63-75.
39. Palozza P, Serini S, Maggiano N, Tringali G, Navarra P, Ranelletti FO, Calviello G: Betacarotene downregulates the steady-state and heregulin-alpha-induced COX-2 pathways in colon cancer cells. J Nutr 2005; 135: 129-136.
40. Valérie B, Biserka R, Xavier L, Alain C, Marie- Paule M, Vincent B: Regulation of HER-2 oncogene expression by cyclooxygenase-2 and prostaglandin E2. Oncogene 2004; 23: 1631-1635.
41. Raja MA, Jean SM: Prostaglandin E2 induces degranulation-independent production of vascular endothelial growth factor by human mast cells. J Immunol 2004; 172: 1227-1236.
42. Mann M, Sheng H, Shao J, Williams CS, Pisacane PI, Sliwkowski MX, DuBois RN: Targeting cyclooxygenase 2 and HER-2/neu pathways inhibits colorectal carcinoma growth. Gastroenterology 2001; 120: 1713-1719.